ClinicalTrials.gg
Not yet recruitingNCT07353541PKU-ESCC-EFUpdated Nov 5, 2026

Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma

An observational study in Esophageal Squamous Cell Carcinoma (ESCC) and Esophageal Fistula, sponsored by Peking University Cancer Hospital & Institute. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Peking University Cancer Hospital & Institute · Observational

How we know

Updated Nov 5, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
32
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This prospective, multi-center, observational registry study (PKU-ESCC-EF) aims to evaluate the safety and effectiveness of a standardized diagnosis and treatment protocol for esophageal fistula (EF) in patients with advanced esophageal squamous cell carcinoma (ESCC). Esophageal fistula is a severe complication that often leads to life-threatening infections and poor nutrition. This study will observe patients receiving a comprehensive management strategy, which includes fistula sealing with esophageal or airway stents, targeted anti-infective therapy, nutritional support, and subsequent systemic anti-tumor therapy. The primary goal is to assess whether this standardized approach can improve overall survival and enable more patients to receive further anti-cancer treatments.

Read the detailed description

This observational registry employs a prospective, single-arm design to recruit eligible patients with newly diagnosed esophageal fistula (tracheoesophageal or mediastinal fistula) complicating unresectable advanced esophageal squamous cell carcinoma. All enrolled participants will receive management according to a predefined standardized diagnostic and therapeutic protocol. The protocol integrates a comprehensive workflow from diagnostic assessment to multidisciplinary intervention: initial diagnosis is supported by clinical manifestations, imaging studies, and endoscopic evaluation, followed by interventional fistula closure using esophageal or airway covered stents selected according to fistula characteristics. Accompanying medical support includes anti-infective therapy, negative pressure suction, anti-reflux treatment, and nutritional support. After achieving adequate fistula control and clinical stabilization, subsequent systemic anti-tumor therapy may be administered based on investigator assessment. Prospective data collection will encompass fistula sealing status, nutritional parameters, quality of life, subsequent anti-tumor treatment rate, overall survival, and exploratory biomarker analysis of biospecimens, thereby providing real-world evidence to standardize management strategies for this serious complication.

02

Conditions studied

  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Esophageal Fistula

Keywords

  • Esophageal Squamous Cell Carcinoma
  • Esophageal Fistula
  • Standardized Management
  • Stent Placement
  • Nutritional Support
  • Observational Study
  • Registry Study
  • Real-world Evidence
03

In context

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

This study's planned enrollment of 32 is below the median of 225 across 88 observational studies indexed under Esophageal Squamous Cell Carcinoma.

Browse Esophageal Squamous Cell Carcinoma studies →

Lead sponsor

Peking University Cancer Hospital & Institute is the lead sponsor of 269 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adult patients (aged 18-75 years) with unresectable, advanced esophageal squamous cell carcinoma (ESCC) who have been newly diagnosed with an esophageal fistula (tracheoesophageal or tracheomediastinal fistula). Eligible participants must have received no more than three prior lines of systemic anti-tumor therapy and must demonstrate adequate organ function and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, making them potential candidates for subsequent anti-tumor treatment following fistula management. Patients with postoperative anastomotic leaks, other active malignancies, uncontrolled infections, significant cardiopulmonary disease, or other specified exclusion criteria will not be eligible for enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation and provision of written .
  • Age between 18 and 75 years (inclusive).
  • confirmed diagnosis of esophageal squamous cell carcinoma.
  • Radiologically confirmed unresectable, advanced disease.
  • Newly diagnosed esophageal fistula (including tracheoesophageal fistula or mediastinal esophageal fistula).
  • Previous receipt of ≤ 3 lines of systemic anti-tumor therapy.
  • (ECOG) performance status of 0 to 2.
  • Adequate organ and marrow function within 7 days prior to potential anti-tumor treatment, as defined by:
  • ≥ 9.0 g/dL
  • (ANC) ≥ 1.5 × 10⁹/L
  • count ≥ 100 × 10⁹/L
  • Total (TBIL) ≤ 1.5 × the (ULN)
  • (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (or ≤ 5 × ULN in the presence of liver )
  • Serum creatinine ≤ 1.5 × ULN
  • Adequate cardiac, pulmonary, and renal function to be eligible for general anesthesia, with no to general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • Patients with postoperative anastomotic fistula.
  • Uncontrolled active bleeding.
  • Presence of a concurrent primary other than esophageal carcinoma.
  • cardiovascular disease, including but not limited to:
  • Heart failure ( Class III-IV)
  • Uncontrolled coronary artery disease, cardiomyopathy, or arrhythmia
  • Uncontrolled hypertension
  • History of myocardial infarction within the past 1 year
  • Neurological or psychiatric disorders that impair cognitive ability, including the presence of central nervous system .
  • Uncontrolled, active severe clinical infection ( > Grade 2 per version 5.0) within 14 days prior to enrollment, including active tuberculosis (this is a for anti-tumor therapy, not for interventional procedures).
  • Known or self-reported infection, or active or .
  • A history of interstitial lung disease (e.g., interstitial pneumonia, pulmonary fibrosis), or evidence of interstitial lung disease on baseline chest X-ray/CT.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
32 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Standardized Management Cohort

    All enrolled patients with advanced esophageal squamous cell carcinoma and newly diagnosed esophageal fistula who receive the standardized diagnosis and treatment protocol.

    Other: Standardized Management Protocol for Esophageal Fistula

Interventions

  • OtherStandardized Management Protocol for Esophageal Fistula

    This is a comprehensive, standardized clinical management protocol for esophageal fistula in advanced esophageal squamous cell carcinoma patients. The protocol integrates multiple standardized components into a unified pathway: (1) systematic diagnosis using iodine-contrast esophagography, chest CT, and endoscopy; (2) interventional fistula sealing with covered esophageal/airway stents selected by fistula characteristics; (3) coordinated adjunctive therapy including anti-infectives, acid suppression, and negative suction; (4) mandatory nutritional assessment with early transition from parenteral to enteral feeding; and (5) a defined pathway for subsequent anti-tumor therapy after clinical recovery. This multi-modal, sequential approach differentiates it from isolated interventions by providing integrated management from diagnosis through nutritional rehabilitation to subsequent oncology care within a standardized framework.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from the diagnosis of esophageal fistula to death from any cause

    Time frame: From date of fistula diagnosis until death from any cause, assessed up to 6 months.

Secondary outcomes

  1. Rate of Subsequent Anti-tumor Therapy

    The proportion of patients who successfully receive/re-initiate systemic anti-tumor therapy after fistula control and clinical recovery.

    Time frame: From date of fistula diagnosis until the initiation of subsequent anti-tumor therapy, assessed through study completion (up to 6 months).

  2. Fistula Sealing Success Rate

    The success rate of fistula sealing, evaluated as either Complete Remission (CR) or Partial Remission (PR) according to the protocol's criteria.

    Time frame: At 2 weeks and 4 weeks after the initial fistula intervention.

  3. Nutritional Status (NRS 2002)

    Nutritional risk will be assessed using the Nutritional Risk Screening 2002 (NRS 2002) tool. The total NRS 2002 score is derived from the sum of three components: Nutritional Status Impairment Score (range: 0-3 points), Disease Severity Score (range: 0-3 points), and Age Adjustment (1 point if age ≥70 years; 0 points otherwise). The total score ranges from 0 to 7 points. A higher total score indicates a greater nutritional risk (i.e., a worse outcome). In accordance with the original validation, a total score of ≥3 points is considered indicative of nutritional risk.

    Time frame: From baseline through study completion (up to 6 months).

  4. Nutritional Status (PG-SGA)

    Nutritional status will be assessed using the Patient-Generated Subjective Global Assessment (PG-SGA) tool. The PG-SGA yields two primary outcomes: 1. Global Rating Categories: Patients are classified as Category A (Well nourished), Category B (Moderately malnourished or suspected of malnourishment), or Category C (Severely malnourished). 2. Total PG-SGA Score: A quantitative score is calculated from patient-generated and professional assessment components. The total score ranges from 0 to approximately 35 points. A higher score indicates a worse nutritional status and outcome (i.e., greater risk or severity of malnutrition). In clinical practice, a score of 4 or higher typically triggers the need for nutritional intervention.

    Time frame: From baseline through study completion (up to 6 months).

  5. Quality of Life (QOL)

    Quality of Life will be assessed using the Functional Assessment of Cancer Therapy - Esophageal Cancer subscale (FACT-E). The FACT-E is composed of the general cancer module (FACT-G) and an esophageal cancer-specific subscale. The total score ranges from 0 to 180 points. A higher score indicates a better quality of life (i.e., a better outcome).

    Time frame: From baseline through study completion (up to 6 months).

  6. Incidence of Adverse Events (AEs)

    Safety and tolerability assessed by the incidence and severity of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0.

    Time frame: From the start of the standardized management protocol until 30 days after the last intervention or through study completion, whichever comes first.

Other outcomes

  1. Percentage of Participants with PD-L1 Positive Expression in Tumor Tissue

    PD-L1 expression will be assessed in baseline tumor tissue samples via immunohistochemistry (IHC). The result will be reported as the percentage of tumor cells with positive membrane staining (e.g., using Tumor Proportion Score, TPS) and/or combined positive score (CPS), as appropriate.

    Time frame: At baseline (time of fistula diagnosis).

  2. EGFR Expression Level in Tumor Tissue

    EGFR expression will be assessed in baseline tumor tissue samples via immunohistochemistry (IHC). The result will be reported using a standardized scoring system (e.g., H-score or percentage of positive cells).

    Time frame: At baseline (time of fistula diagnosis).

  3. Ki-67 Proliferation Index in Tumor Tissue

    Ki-67 expression will be assessed in baseline tumor tissue samples via immunohistochemistry (IHC). The result will be reported as the Ki-67 proliferation index (percentage of positively stained tumor cell nuclei).

    Time frame: At baseline (time of fistula diagnosis).

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Oct 2028, 23 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Feb 2026 → Nov 2026, primary completion Apr 2026 → Oct 2028 and completion Apr 2026 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Jan 20, 2026
StartEst.
Nov 1, 2026was Feb 2026
Primary completionEst.
Oct 1, 2028was Apr 2026
CompletionEst.
Oct 1, 2028was Apr 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 1, 2026→Nov 1, 2026
Nov 5, 2026
Primary completion
Apr 1, 2026→Oct 1, 2028
Nov 5, 2026
Study completion
Apr 1, 2026→Oct 1, 2028
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Start date Feb 1, 2026→Nov 1, 2026
    Primary completion Apr 1, 2026→Oct 1, 2028
    Study completion Apr 1, 2026→Oct 1, 2028
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07353541
Collaborators
Emergency General Hospital, Beijing GoBroad Hospital
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Zhihao Lu
Contact
pppeirain@126.com
+85201088196561

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion